Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization

Area of Science:

• Pharmaceutical Science
• Materials Science
• Drug Delivery

Background:

• Poorly water-soluble drugs often exhibit low bioavailability.
• Amorphous solid dispersions and co-amorphous systems (CAMs) are strategies to enhance solubility.
• Recrystallization during processing can compromise the stability of amorphous systems.

Purpose of the Study:

• To evaluate the water and heat stability of amorphous olanzapine (OLZ) and its CAMs.
• To assess the impact of pharmaceutical processing (wet granulation, pelletization) on OLZ-CAM stability.
• To compare the performance of OLZ-CAMs with crystalline olanzapine.

Main Methods:

• Characterization using calorimetry, diffractometry, and spectroscopy.
• Dissolution testing to evaluate drug performance.
• Exposure to water and heat stress conditions during simulated processing.

Main Results:

• Amorphous OLZ recrystallized upon exposure to water and heat.
• OLZ-CAMs stabilized with saccharin (SAC) maintained amorphous content, demonstrating enhanced stability.
• OLZ-CAMs exhibited higher solubility and dissolution rates compared to crystalline OLZ.
• In situ co-amorphization during granulation offers potential for streamlined manufacturing.

Conclusions:

• OLZ-CAMs provide superior stability against water and heat compared to amorphous OLZ.
• CAM formation is a viable strategy to improve the bioavailability and processing of poorly soluble drugs like olanzapine.
• In situ co-amorphization presents an opportunity for process simplification and cost reduction in pharmaceutical manufacturing.